ArticleCureus2026
Association of Glutathione S-transferase Gene Polymorphisms With Hepatocellular Carcinoma in Patients From Maharashtra, India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is a major global health burden with high mortality. Genetic variations in detoxification enzymes, particularly glutathione S-transferases (GSTs), may influence predisposition to HCC. This population-specific study investigates the relationship between GST gene polymorphisms and the occurrence of HCC in India.
methodsA case-control study was conducted involving 380 individuals (190 confirmed HCC patients and 190 age- and gender-matched healthy controls) from India. Genotyping for GSTM1 (625 bp and 215 bp) and GSTT1 variants was performed using polymerase chain reaction (PCR), while the GSTP1 Ile105Val (A→G) polymorphism was analyzed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Associations between genotypes and the occurrence of HCC were evaluated using the chi-square test and odds ratio (OR) with a 95% confidence interval (CI); a p-value of ≤0.05 was considered statistically significant.
resultsThe GSTT1 (480 bp) null genotype exhibited a statistically significant positive association with the occurrence of HCC (OR=2.681, 95% CI=1.73-4.14; p<0.0001). In contrast, the GSTM1 (215 bp) null genotype demonstrated a significant negative association with the occurrence of HCC (OR=0.135, 95% CI=0.072-0.25; p<0.0001). Similarly, the GSTM1 (625 bp) null genotype also showed a significant negative association with the occurrence of HCC (OR=0.5476, 95% CI=0.364-0.825; p=0.004). GSTP1 heterozygous (adjusted OR=0.517; 95% CI: 0.124-2.15; p=0.364) and variant (adjusted OR=1.28; 95% CI: 0.3-5.49; p=0.737) genotypes showed no significant association with HCC risk after adjustment for confounding factors.
conclusionThe findings indicate that the GSTT1 (480 bp) null genotype is significantly associated with increased susceptibility to HCC in the Maharashtrian population. In contrast, GSTM1 null genotypes (215 bp and 625 bp) appear to confer a protective effect. GSTP1 polymorphism was not significantly associated with HCC risk after adjustment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.